Short answer
Sionna Therapeutics, Inc. (SION) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$27M
- −62.5% YoY
- EPS (diluted)
- −$0.60
- +99.9% YoY
Source: XBRL data from the Sionna Therapeutics, Inc. (SION) Q1 2026 10-Q on SEC EDGAR. USD.
Sionna Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales or other revenue
- Net loss $26.8M vs $16.5M YoY; operating loss $29.6M vs $19.7M
- Worst-performing area: G&A expenses $10.6M vs $6.0M YoY, up $4.6M
- Cash, equivalents and marketable securities $289.9M; operating cash use $21.8M vs $16.3M
- Outlook: funding expected into 2028; Phase 2a and dual-combination topline data anticipated summer 2026
Risk Factors
- No material-change statement provided; filing describes continued clinical-stage, pre-revenue exposure
- Funding runway through 2028 based on $289.9 million cash, equivalents, and marketable securities
- Regulatory approval risk from unpredictable FDA requirements and potential additional trials
- Combination-therapy risk from drug interactions, unforeseen toxicities, and failed clinical trials
- Uninsured cash deposits at major financial institutions, exposing liquidity to institutional failure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sionna Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.